Transplant Genomics
Private Company
Total funding raised: $11M
Overview
Transplant Genomics, founded in 2010 and based in San Diego, develops and commercializes non-invasive molecular diagnostic tests for transplant recipients. Its flagship TruGraf tests use peripheral blood gene expression profiles to monitor graft health, detect subclinical acute rejection, and aid in immunosuppression optimization, aiming to reduce reliance on invasive biopsies. As a commercial-stage diagnostics company under the Eurofins umbrella, it targets the significant unmet need for precise, actionable monitoring in the solid organ transplant market.
Technology Platform
Peripheral blood gene expression profiling (GEP) and donor-derived cell-free DNA (dd-cfDNA) analysis for non-invasive monitoring of transplant graft health and immune status.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
The market is competitive, dominated by CareDx (AlloMap GEP, AlloSure dd-cfDNA) and Natera (Prospera dd-cfDNA). These companies have first-mover advantage and established sales channels. Transplant Genomics differentiates by offering both GEP and dd-cfDNA under one umbrella and focusing on organ-specific signatures, but must compete aggressively on clinical data, price, and ease of use to gain market share.